In our in-house cohort (Supplementary Table S6), the expression levels of CD274, HMGB2, RAC2, RIN3, and SOD3 were elevated in WHO grade IV gliomas compared to grades II/III. The gene discussed is HMGB2; the disease is central nervous system cancer.